Can a diabetic's likelihood of developing complications depend on picking the right doctor? A study suggests it can.
FOR IMMEDIATE RELEASE FEBRUARY 11, 2014
AJMC Study: Better Diabetes Care Meant Fewer Complications
PLAINSBORO, N.J. — What if the chance of having complications from diabetes came down to picking the right doctor?
A study of a group of manufacturing workers published in the most recent issue of The American Journal of Managed Care found that better care can make a difference, and can even compensate for being sicker at the outset.
Better care, in this case, meant having a doctor who tracked three key health measures: glycated hemoglobin, lipids and microalbuminuria. The study tracked 1,797 employees with diabetes from Alcoa Aluminum, who were followed from 2003 to 2009. Those with diabetes who had all three measures tracked starting in the first year of the study were compared over time with those who received less complete testing.
Since the study subjects all had the same health plan, researchers could isolate the effect of the quality of care itself, not coverage.
Researchers compared long-term health results of those diabetics whose doctors tracked all three measures, compared with diabetics whose doctors did not. The study looked at time to progression for four common complications from diabetes: coronary artery disease, stroke, heart failure and renal disease.
Differences between the two groups were significant. Those who did not have all three health measures tracked were more likely to have heart failure or renal disease, and those who had all three measured tracked from the beginning were less likely to have complications overall. Notably, only 15 percent of the diabetes in the group had all three measured checked at the beginning of the study period.
Researchers noted the difficulty in assessing how care plays out over time. Did those patients who had the most symptoms at the beginning seek better care, or take better of themselves in other ways? “It is noteworthy that in the primary test of the hypothesis, the baseline characteristics created an uneven playing field, with more ostensibly sick patients having a higher rate of better care; thus, the deck was stacked against those with better care having better outcomes, an effect that began to be visually apparent in the third observation year,” the researchers wrote. For the full study, click here.
CONTACT: Mary Caffrey (609) 716-7777 x 144
www.ajmc.com Follow us @EBDiabetes
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More